What are the key challenges in secondary prevention in cardiovascular care, and how can guidelines be translated into practice to optimize patient management?

Our host, Dr. Michael Levi, takes a deep dive into secondary prevention in cardiovascular care, with Dr. Lior Bibas, a cardiologist and critical care physician.

In this episode, our experts unpack the core principles of secondary prevention in cardiovascular care, exploring how to minimize recurrent events through targeted lipid management, lifestyle interventions, and evidence-based pharmacologic strategies. From defining optimal LDL, non-HDL, and ApoB thresholds to sequencing different pharmacological agents, the discussion offers a practical roadmap for achieving aggressive lipid lowering in high-risk patients.

Discover actionable insights grounded in international guidelines that will strengthen your approach to optimizing cardiovascular risk reduction and delivering long-term protection for patients following a vascular event.

Don’t miss the conversation! 

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. 

Declaration of conflict of interest: 

Dr. Michael Levi:

• None.

Dr. Lior Bibas:

• None.

MAT-CA- 2600003 V(1.0) App 01/26

How is the evolving understanding of lipoprotein A reshaping our approach to prevention of heart disease?

Our host, Dr. Michael Levi, takes a deep dive into this topic with Dr. Lior Bibas, a cardiologist and critical care physician at Pierre Boucher Hospital and the Montreal Heart Institute.

In this episode, our experts explain why lipoprotein A is gaining prominence as a key risk factor for cardiovascular disease, discussing its unique properties and clinical implications. They share insights from their clinical practices, revealing how a deeper understanding of specific lipid markers is influencing both primary and secondary prevention strategies and aggressive treatment decisions. Tune in for a glimpse into the future of personalized heart care and emerging therapies that could transform treatment.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Michael Levi:

· None.

Dr. Lior Bibas:

· None.

MAT-CA-2501196 V(1.0) App 09/25

Secondary prevention of atherosclerotic cardiovascular disease (ASCVD) often requires the use of lifelong therapies. How can healthcare providers promote adherence to secondary prevention interventions to help high-risk patients achieve their lipid goals?

Our host, Dr. Liam Brunham, takes a deeper look into this topic with Dr. Tara Sedlak, a cardiologist at Vancouver General Hospital and BC Women's Hospital, and Director of the Leslie Diamond Women's Heart Health Clinic.

Despite the availability of lipid-lowering therapies that reduce the risk of morbidity and mortality, many patients with established ASCVD are not achieving guideline-recommended lipid targets. This episode takes a closer look at some of the factors contributing to this care gap, with a focus on the reasons why patients may be discontinuing their medications. Our experts discuss practical strategies to optimize adherence and secondary prevention for improved outcomes. In addition, they also explore the various ways in which treatments can be personalized to individual patient needs, and how best to support and empower patients in their journey toward optimal lipid management.

Don’t miss the conversation!

The views and opinions expressed in this episode are those of the speakers and do not necessarily reflect the views or positions of any entities they represent.

Declaration of conflict of interest:

Dr. Brunham:

• Direct financial relationship including receipt of honoraria: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Membership on advisory boards or speaker’s bureau: Sanofi, Amgen, HLS, Pfizer, Ultragenyx, Novartis, Novo Nordisk. Funded grants, research, or clinical trials: Amgen, Novartis, Ionis.

Dr. Sedlak:

• Direct financial relationship including receipt of honoraria: Amgen, Novo Nordisk, Sanofi, KYE Pharmaceuticals, Pendopharm, Boehringer Ingelheim, Eli Lilly, Bayer, Novartis, Pfizer. Membership on advisory boards or speaker’s bureau: Amgen, Novo Nordisk, KYE Pharmaceuticals, Boehringer Ingelheim, Lilly.

MAT-CA-2301816 App Dec 2023